Streptococcus pneumoniae type 4 capsular polysaccharide antigen
- Generic Name
- Streptococcus pneumoniae type 4 capsular polysaccharide antigen
- Brand Names
- Pneumovax 23, Prevnar 13, Vaxneuvance
- Drug Type
- Biotech
- Unique Ingredient Identifier
- CGS5KI3Q2M
- Background
Streptococcus pneumoniae type 4 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 4 of Streptococcus pneumoniae. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
- Associated Conditions
- Pneumococcal Infection
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
Phase 3
Not yet recruiting
- Conditions
- Chickenpox
- Interventions
- Biological: Candidate varicella vaccineBiological: Marketed varicella vaccine
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 900
- Registration Number
- NCT06855160
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
Phase 3
Not yet recruiting
- Conditions
- Chickenpox
- Interventions
- Biological: Marketed varicella vaccineBiological: Investigational varicella vaccine
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 600
- Registration Number
- NCT06806137
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
Phase 3
Recruiting
- Conditions
- Chickenpox
- Interventions
- Biological: Investigational varicella vaccine_Lot 1Biological: Investigational varicella vaccine_Lot 2Biological: Investigational varicella vaccine_Lot 3Biological: Marketed varicella vaccine_Lot 1Biological: Marketed varicella vaccine_Lot 2
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1840
- Registration Number
- NCT06740630
- Locations
- 🇺🇸
GSK Investigational Site, Layton, Utah, United States
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
Phase 3
Recruiting
- Conditions
- Chickenpox
- Interventions
- Biological: Investigational varicella vaccineBiological: Marketed varicella vaccineBiological: Measles, mumps, and rubella vaccine
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 750
- Registration Number
- NCT06693895
- Locations
- 🇺🇸
GSK Investigational Site, West Covina, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath